← Episode briefing

Joe Rogan Experience #2576 - Dr. Peter McCullough · Aired Nov 4, 2026

UnverifiedDr. Peter McCullough (matched by voice)

Claim summary · not a verbatim quotation

McCullough says spike-detox supplements clear spike protein and treat vaccine cardiac injury.

Hear the moment · 1:54:32 ↗

The finding

What remains unresolved

Laboratory nattokinase spike degradation is real preliminary evidence. It does not establish that an oral nattokinase/bromelain/curcumin product treats human myocarditis or prevents defibrillator need. AHRQ found insufficient clinical research for this purpose. McCullough discloses a commercial role and cautions about blood-thinner use later in the discussion.

Read the supporting source · effectivehealthcare.ahrq.gov ↗
Quick answer & review status

Quick answer

Is it true that McCullough says spike-detox supplements clear spike protein and treat vaccine cardiac injury?

We can't say yet. Laboratory nattokinase spike degradation is real preliminary evidence. It does not establish that an oral nattokinase/bromelain/curcumin product treats human myocarditis or prevents defibrillator need. Dr. Peter McCullough said it (matched by voice) on Joe Rogan Experience #2576 - Dr. Peter McCullough, aired Nov 4, 2026, at 1:54:32. We couldn't settle it from the evidence we captured, so it stays an open question, not a false claim. The supporting source is effectivehealthcare.ahrq.gov, linked below.

The context belongs here.

No separately verified on-air correction is recorded for this check. That is not a claim that nobody corrected it.

Attribution
Not independently confirmed in this record
Editorial context review
Not recorded; generated finding
Coverage
One selected claim from the episode

Revisions to this check

No dated revision is recorded here. Older checks may predate this log.

Challenge this finding or add context →
Stay curious. Stay up to date.

Keep the evidence coming.

Follow new checks in your RSS reader, or catch up with the weekly briefing on the site.

Follow the RSS feed

Email signup is currently unavailable.

Prefer to catch up here? Read the weekly briefing.